Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Abedini, S; Holme, I; Marz, W; Weihrauch, G; Fellstrom, B; Jardine, A; Cole, E; Maes, B; Neumayer, HH; Gronhagen-Riska, C; Ambuhl, P; Holdaas, H.
Inflammation in Renal Transplantation
CLIN J AM SOC NEPHROL. 2009; 4(7): 1246-1254.
Doi: 10.2215/CJN.00930209
[OPEN ACCESS]
Web of Science
FullText
FullText_MUG
Google Scholar
- Co-authors Med Uni Graz
- März Winfried
- Weihrauch Gisela
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Background and objectives: Renal transplant recipients experience premature cardiovascular disease and death. The association of inflammation, all-cause mortality, and cardiovascular events in renal transplant recipients has not been examined in a large prospective controlled trial. Design, setting, participants, & measurements: ALERT was a randomized, double-blind, placebo-controlled study of the effect of fluvastatin on cardiovascular and renal outcomes in 2102 renal transplant recipients. Patients initially randomized to fluvastatin or placebo in the 5- to 6-yr trial were offered open-label fluvastatin in a 2-yr extension to the original study. The association between inflammation markers, high-sensitivity C-reactive protein (hsCRP), and IL-6 on cardiovascular events and all-cause mortality was investigated. Results: The baseline IL-6 value was 2.9 +/- 1.9 pg/ml (n = 1751) and that of hsCRP was 3.8 +/- 6.7 mg/L (n = 1910). After adjustment for baseline values for established risk factors, the hazard ratios for a major cardiac event and all-cause mortality for IL-6 were 1.08 [95% confidence interval (Cl), 1.01 to 1.15, P = 0.0181 and 1.11 (95% Cl, 1.05 to 1.18, P < 0.001), respectively. The adjusted hazard ratio for hsCRP for a cardiovascular event was 1.10 (95% CI, 1.01 to 1.20, P = 0.027) and for all-cause mortality was 1.15 (95% Cl, 1.06 to 1.1.25, P = 0.049). Conclusions: The inflammation markers IL-6 and hsCRP are independently associated with major cardiovascular events and all-cause mortality in renal transplant recipients. Clin J Am Soc Nephrol 4: 1246-1254, 2009. doi: 10.2215/CJN.00930209